Clinical Trials · NCT02849080
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 504
- Start date
- Sep 2016
- Locations
- 83 sites, 10 countries
- Primary endpoint
- Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no)